Pharmaceutical companies have invested heavily in AI. Yet for many commercial organizations, the expected business impact remains out of reach.
The challenge is no longer access to AI. It is turning AI into something commercial teams can rely on every day.
Despite widespread experimentation, most organizations remain stuck in pilot mode. Fragmented data, disconnected technology ecosystems, regulatory complexity, and ongoing platform transitions continue to prevent AI from scaling across the enterprise.
At the same time, AI itself is evolving. As agentic AI and retrieval-augmented generation (RAG) mature, organizations have an opportunity to move beyond assistants that generate responses toward systems that can reason across enterprise data, execute complex workflows, and deliver trusted decision support at scale.
This is the challenge the Field Analytics Control Tower (FACT) was built to address.
FACT is a platform-agnostic AI control plane designed for pharmaceutical commercial teams. It unifies CRM data, incentive compensation systems, field activity, and unstructured engagement notes into a single conversational intelligence layer, enabling sales leaders, commercial operations, and field teams to access trusted insights when they need them.
Built on a scalable multi-agent architecture and powered by the Model Context Protocol (MCP), FACT helps organizations navigate evolving technology environments while maintaining a consistent user experience, enterprise-grade security, and regulatory compliance.
Inside the whitepaper, you’ll discover:
- Why agentic AI represents the next frontier for pharmaceutical commercialization
- The challenges preventing AI adoption from scaling across the enterprise
- How a multi-agent architecture enables faster insights and greater operational agility
- Best practices for governance, observability, and compliance
- Real-world results, including up to 85% reduction in reporting effort, 15% improvement in HCP targeting accuracy, and significant first-year ROI
Download the whitepaper to see how pharmaceutical organizations are moving AI from isolated pilots to everyday commercial decision-making.
